M&T Bank Corp Grows Position in Novo Nordisk A/S $NVO

Key Points

• M&T Bank Corp raised its stake in Novo Nordisk by 302.2% in Q4, acquiring an additional 238,063 shares to hold 316,847 shares worth about $16.12 million.
• Company fundamentals and pipeline look positive: Novo Nordisk beat quarterly estimates ($1.01 EPS vs. $0.90 expected; $12.43B revenue) and reported that oral semaglutide met its primary endpoint in a late‑stage pediatric diabetes trial, with plans to seek U.S. approval.
• Market sentiment is mixed: the consensus rating is "Hold" (average target $65.56) while the stock trades near $38.54 versus a 12‑month high of $81.44, and analyst downgrades plus GLP‑1 competition have increased volatility.

M&T Bank Corp raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 302.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 316,847 shares of the company's stock after purchasing an additional 238,063 shares during the quarter. M&T Bank Corp's holdings in Novo Nordisk A/S were worth $16,121,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Smith Chas P & Associates PA Cpas increased its position in shares of Novo Nordisk A/S by 105.3% in the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock worth $22,497,000 after acquiring an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC grew its stake in shares of Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company's stock valued at $17,267,000 after buying an additional 37,453 shares in the last quarter. Markel Group Inc. grew its stake in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company's stock valued at $131,436,000 after buying an additional 110,061 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $1,294,000. Finally, WCM Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 3.7% in the third quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company's stock valued at $151,636,000 after buying an additional 97,477 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on NVO. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, February 23rd. Zacks Research upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Jefferies Financial Group upgraded Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research note on Thursday, February 12th. Finally, CICC Research began coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They set an "outperform" rating and a $73.50 price target for the company. Four equities research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Price Performance

NVO opened at $38.54 on Friday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a fifty day simple moving average of $39.30 and a 200 day simple moving average of $47.94. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The firm has a market cap of $172.07 billion, a price-to-earnings ratio of 11.11, a PEG ratio of 9.32 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Equities research analysts expect that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were paid a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date was Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is 50.43%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage trial: oral semaglutide met its main goal in a trial of 10–17 year olds with type 2 diabetes, supporting a planned U.S. approval push and expanding the drug’s potential label into pediatrics — a clear pipeline positive. Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Regulatory/launch implication: company and press reports say Novo plans to seek approval for the oral semaglutide pill to treat younger patients — success here could broaden long‑term revenue and strengthen the oral GLP‑1 franchise. Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients
• Neutral Sentiment: Market reaction note: coverage highlights that NVO has dipped more than broader markets today, reflecting investor caution despite the clinical win. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market
• Neutral Sentiment: Industry context: broader longevity/GLP‑1 debate and sector capital flows are keeping large cap GLP‑1 names (including Novo) in focus but add volatility rather than immediate directional news. The Longevity Trade Is No Longer a Buzzword — It’s a $120 Billion Market
• Negative Sentiment: Analyst downgrade/target cut: Citigroup trimmed its price target for Novo (maintaining a Neutral rating), signaling lower near‑term expectations and contributing to selling pressure. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Competitive/strategy concerns: commentary questions whether the GLP‑1 “golden age” can continue for incumbents and flags intensifying competition — a negative for long‑term growth multiple assumptions. Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It?
• Negative Sentiment: Distribution/competitive move: Eli Lilly’s expanding direct‑to‑consumer channels (e.g., LillyDirect partnerships) may intensify commercial competition for GLP‑1 products and distribution, a potential headwind for market share. Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma?

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.